The recent surge in funding into specialized pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for revolutionary treatments and impressive returns is certain, the associated risks are also notable. Many of